NCT Number: NCT00462540
A Crossover Study in the Treatment of Patients With COPD
The purpose of this study is to compare the efficacy of Formoterol Fumarate Inhalation Solution (FFIS) 20 mcg BID to Combivent® Inhalation Aerosol [2 inhalations from metered dose inhaler (MDI)of 18 mcg ipratropium bromide and 103 mcg albuterol sulfate QID], and to Compare the preference/compliance of BID nebulization to QID use of MDI
Looking for future studies?
Notify MeKey information
Conditions
Age range
40 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Research Site, San Diego, California, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Diagnosis of COPD
- Smoker or exsmoker with at least 10 years smoking at least one pack of cigarettes per day
- Meet lung function requirements
Exclusion criteria
- Diagnosis of Asthma
- Significant disease other than COPD
- Female pregnant or lactating or planning to become pregnant
Treatment and study plan
Ipratropium bromide 18 mcg and albuterol sulfate 103 mcg
DrugPrimary outcomes
-
Lung function after 2 weeks of treatment
Secondary outcomes
-
Lung function at each time point, patient questionnaires, medication compliance,
-
adverse events, clinical labs, vital signs, ECGs, physical exams
Interested in participating?
Looking for future studies?
Notify MeSponsors and collaborators
Lead sponsor
Dey
Industry
Registry information
Important dates
- Study start
- 2007
- Primary completion
- 2007
- Study completion
- 2007
- First posted
- Apr 19, 2007
- Registry last updated
- Mar 4, 2009
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Clinical and Hemodynamic Correlates of Different Polarities of HD-tDCS in COPD
NCT07831629
Chronic Disease, Chronic Obstructive Pulmonary Disease
João Pessoa, Brazil
View Trial DetailsA Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
NCT06208306
Chronic Disease, Chronic Obstructive Pulmonary Disease
Chandler, Arizona, United States
View Trial DetailsGoals of Care Conversations Study
NCT05001009
Brain Diseases, Cancer
Palo Alto, California, United States
View Trial DetailsClinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)
NCT07016412
Chronic Disease, Chronic Obstructive Pulmonary Disease
Dothan, Alabama, United States
View Trial Details